Navigation Links
RBC Life Sciences Reports Sales and Earnings Growth in 2010
Date:3/8/2011

IRVING, Texas, March 8, 2011 /PRNewswire/ -- (RBC Life Sciences: OTC Bulletin Board: RBCL) -- RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported a 13% increase in consolidated net sales to $28.2 million for the year ended December 31, 2010, compared to net sales of $24.9 million for the same period during 2009. For 2010, the Company reported net earnings of $558,000, or $0.02 per diluted share, compared to a net loss of $335,000, or $0.02 per diluted share, during 2009.

"We significantly improved our financial performance in 2010 reporting sales growth in both our Nutritional Products segment and Medical Products segment," said RBC Life Sciences President and CEO, Clinton H. Howard.  "We were particularly pleased to report sales growth of 22% to our international licensees, which is our largest revenue channel.  This growth in sales along with expense reductions affected during 2010 resulted in an $893,000 improvement in net operating results and a return to profitability in 2010."

During 2010, net sales of Nutritional Products increased 15% to $21.6 million while net sales of Medical Products increased 6% to $6.5 million.

About RBC Life SciencesThrough wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's Web site at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.RBC Life Sciences, Inc.Summary Results of Operations(in thousands, except per share data)

(unaudited)Years Ended December 31,20102009Net sales

$

28,157$

24,925Gross profit

13,68612,802Operating profit (loss)

1,044(160)Earnings (loss) before income taxes

891(324)Provision for income taxes

33311Net earnings (loss)

558(335)Earnings (loss) per share - basic

$

0.03$

(0.02)Earnings (loss) per share - diluted

0.02(0.02)Weighted average shares outstanding - basic

21,99921,921Weighted average shares outstanding - diluted

22,43621,921RBC Life Sciences, Inc.Condensed Consolidated Balance Sheets(in thousands)

(unaudited)December 31,20102009AssetsCash and cash equivalents

$

4,220$

3,972Inventories

5,3435,344Other current assets

1,6961,914Total current assets

11,25911,230Other assets

7,0857,383Total assets

$

18,344$

18,613Liabilities and shareholders' equityAccounts payable and accrued liabilities

$

3,087$

2,729Deferred revenue

2,4903,669Other current liabilities

168156Total current liabilities

5,7456,554Other liabilities

2,7232,840Shareholders' equity

9,8769,219Total liabilities and shareholders' equity

$

18,344$

18,613
'/>"/>

SOURCE RBC Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Research and Markets has announced the addition of the ... Forecast" report to their offering. ... Proton Therapy Market in Italy will ... There are currently three proton therapy centers in Italy ... Italy , the first patients were treated with proton ...
(Date:3/29/2017)... and Markets has announced the addition of the "South Korean Proton ... report to their offering. ... The South Korean Proton Therapy Market is expected to almost triple ... Therapy Market for South Korea was valued at ... plays an important role in delivering comprehensive cancer care to children and ...
(Date:3/29/2017)... HUNTINGTON BEACH, Calif. , March 29, 2017 ... treatment have recognized remote monitoring devices like  Soberlink ... monitoring.   The consensus paper, published in early ... "feasible, practical and valuable in managing patient recovery." ... published in the Journal of Addiction Medicine, detail ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest ... in two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy ...
(Date:3/29/2017)... ... , ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is ... or without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. ... patients receive early treatment, they may achieve straight teeth with less treatment in their ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
Breaking Medicine News(10 mins):